Tech Company Financing Transactions
Stealth BioTherapeutics Funding Round
On 6/19/2018, Stealth BioTherapeutics announced $100 million in financing from Pivotal bioVenture Partners, Atlantis Investment Management and BVCF.
Transaction Overview
Company Name
Announced On
6/19/2018
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds from the financings will be used to initiate a phase 2b clinical trial of Stealth's lead compound, elamipretide, in intermediate dry age-related macular degeneration, for which positive interim results were recently reported and full results are expected later in 2018.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
275 Grove St. 3-107
Newton, MA 02466
USA
Newton, MA 02466
USA
Phone
Website
Email Address
Overview
Stealth BioTherapeutics (Nasdaq: MITO) is an innovative biopharmaceutical company committed to bringing patients mitochondria-targeted therapies to treat both common and rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Reenie McCarthy
Chief Financial Officer
Daniel Geffken
Chief Scientific Officer
Mark Bamberger
Vice President
Deb Gouveia
VP - Bus. Development
Brian Blakey
VP - General Counsel
Henry Hess
VP - Operations
Marty Redmon
VP - Regulatory Affairs
David Schubert
Browse more venture capital transactions:
Prev: 6/19/2018: Pulumi venture capital transaction
Next: 6/19/2018: Tray.io venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs